Chong Kun Dang Signs KIO-301 Deal

Chong Kun Dang CEO Kim Young-joo (left) and Kiora Pharmaceuticals President and CEO Brian M. Strem are taking a commemorative photo after signing a licensing agreement for the development and commercialization of the new drug candidate 'KIO-301' for the treatment of retinitis pigmentosa at the Chong Kun Dang headquarters in Chungjeong-ro. (Provided by Chong Kun Dang) Chong Kun Dang has joined…